imv-inc产品代理

产品分类 > 科研耗材 > imv-inc产品代理

imv-inc产品代理

我们为难以治疗的癌症推进新型免疫疗法
IMV Inc. 是一家临床阶段的制药公司,有可能通过开发一流的有效 T 细胞靶向癌症免疫疗法来创造历史。 我们已经建立了一个前所未有的传递平台 (DPX),它可以将靶向免疫细胞直接生成到人体中,从而产生强大而持久的能力来摧毁癌症。 DPX 是驱动我们的主要候选药物 maveropepimut-S (DPX-Survivac) 的引擎,该药物已成功完成多项 1/1b 期试验,在晚期复发性卵巢癌和弥漫性大 B 细胞淋巴瘤中取得同类最佳结果( DLBCL)。
价格: 0.00

We Advance   Novel Immunotherapies for Hard-to-Treat Cancers

   

IMV Inc. is a clinical-stage pharmaceutical company that has the potential to make history by developing a first-in-class effective T cell-targeted immune therapy for cancer. We have built an unprecedented delivery platform (DPX) that generates targeted immune cells directly into the human body, which produces robust, and sustained capabilities to destroy cancer. DPX is the engine that drives our lead drug candidate, maveropepimut-S (DPX-Survivac), which has successfully completed multiple Phase 1/1b trials, generating best-in-class results in advanced recurrent ovarian cancer and Diffuse Large B Cell Lymphoma (DLBCL).